Biosimilars Council & The Atlantic: The Next Drugs: The Future for Biosimilars

Biosimilars not only have the unique ability to provide patients with much-needed access to lower-cost complex therapies, but also offer the potential for billions in patient, insurer and health system savings.  But there are barriers that deny patients access to these safe, affordable medications.

Tomorrow morning at 8:00 a.m. ET, we’ll discuss these topics – and more – with a panel of experts at The Next Drugs: An Atlantic Policy Update on Biosimilars.

For more information please visit the event page or email Carly Spraggins at [email protected].

The Biosimilars Council is now on Twitter, Facebook, and LinkedIn. Follow us for the latest updates on biosimilars.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.